Royalty Pharma to pay Ferring $300 million upfront and a potential $200 million milestone payment in exchange for royalties on the sales of Ferring’s intravesical gene therapy Adstiladrin® (nadofaragene firadenovec-vncg)Transaction
Royalty Pharma plc (RPRX) and Ferring Pharmaceuticals Enter $500M Royalty Agreement for New Intravesical Gene Therapy Adstiladrin streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.